Penumbra (PEN) Revenue Growth (3y) (2017 - 2026)
Penumbra (PEN) Revenue Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 4.63% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 8.01% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 4.70% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 15.36% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | 10.52% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 17.14% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 2.92% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 0.73% |
| 10 | Penumbra | 12.55 Bn | 11.94 Bn | 253.41 Mn | 15.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.79% |
| Dec 31, 2025 | 20.33% |
| Sep 30, 2025 | 18.40% |
| Jun 30, 2025 | 17.67% |
| Mar 31, 2025 | 16.71% |
| Dec 31, 2024 | 15.64% |
| Sep 30, 2024 | 16.56% |
| Jun 30, 2024 | 17.56% |
| Mar 31, 2024 | 18.09% |
| Dec 31, 2023 | 19.48% |
| Sep 30, 2023 | 21.50% |
| Jun 30, 2023 | 35.50% |
| Mar 31, 2023 | 20.69% |
| Dec 31, 2022 | 15.05% |
| Sep 30, 2022 | 15.27% |
| Jun 30, 2022 | 15.79% |
| Mar 31, 2022 | 16.65% |
| Dec 31, 2021 | 19.09% |
| Sep 30, 2021 | 19.36% |
| Jun 30, 2021 | 18.89% |